Congleton Jon's Form 4 filing
Mineralys Therapeutics, Inc. (MLYS) · filed Jul 12, 2024
- Accession no.
- 0001933414-24-000033
- Filed
- Jul 12, 2024
- Trade date
- Jul 11, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $210.1K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Congleton JonCIK 0001644975 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 11, 2024 | Common Stock | SSaleDisposed | −15,746 | $13.34F2 | −$210,051.64 | 911,212 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.96 to $13.76. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
Referenced by the price of 1 transaction in Table I.